Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Capital Expenditures (2019 - 2020)

Cyclerion Therapeutics (CYCN) has 2 years of Capital Expenditures data on record, last reported at $35000.0 in Q4 2020.

  • For Q4 2020, Capital Expenditures fell 95.19% year-over-year to $35000.0; the TTM value through Dec 2022 reached $44000.0, down 97.04%, while the annual FY2021 figure was $7000.0, 99.54% down from the prior year.
  • Capital Expenditures reached $35000.0 in Q4 2020 per CYCN's latest filing, up from $9000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.8 million in Q1 2019 and bottomed at -$1.3 million in Q2 2019.